Literature DB >> 27618979

Adjuvant immunotherapy in resected early non-small cell lung cancer-battle lost, hopefully not the war!

Branislav Jeremic1, Nikola Cihoric2, Pavol Dubinsky3, Nenad Filipovic4.   

Abstract

Entities:  

Year:  2016        PMID： 27618979      PMCID： PMC4999750          DOI： 10.21037/jtd.2016.07.11

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  22 in total

1.  Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

Authors:  Marie Wislez; Fabrice Barlesi; Benjamin Besse; Julien Mazières; Patrick Merle; Jacques Cadranel; Clarisse Audigier-Valette; Denis Moro-Sibilot; Laure Gautier-Felizot; François Goupil; Aldo Renault; Elisabeth Quoix; Pierre-Jean Souquet; Anne Madroszyck; Romain Corre; David Pérol; Franck Morin; Gérard Zalcman; Jean-Charles Soria
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

2.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

3.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

4.  A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

Authors:  G Giaccone; L A Bazhenova; J Nemunaitis; M Tan; E Juhász; R Ramlau; M M van den Heuvel; R Lal; G H Kloecker; K D Eaton; Q Chu; D J Dunlop; M Jain; E B Garon; C S Davis; E Carrier; S C Moses; D L Shawler; H Fakhrai
Journal:  Eur J Cancer       Date:  2015-08-14       Impact factor: 9.162

Review 5.  Harnessing the immune system for the treatment of non-small-cell lung cancer.

Authors:  Julie R Brahmer
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

6.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Authors:  Glenwood D Goss; Chris O'Callaghan; Ian Lorimer; Ming-Sound Tsao; Gregory A Masters; James Jett; Martin J Edelman; Rogerio Lilenbaum; Hak Choy; Fadlo Khuri; Katherine Pisters; David Gandara; Kemp Kernstine; Charles Butts; Jonathan Noble; Thomas A Hensing; Kendrith Rowland; Joan Schiller; Keyue Ding; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

7.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Authors:  Gerold Bepler; Charles Williams; Michael J Schell; Wei Chen; Zhong Zheng; George Simon; Shirish Gadgeel; Xiuhua Zhao; Fred Schreiber; Julie Brahmer; Alberto Chiappori; Tawee Tanvetyanon; Mary Pinder-Schenck; Jhanelle Gray; Eric Haura; Scott Antonia; Juergen R Fischer
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

9.  A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.

Authors:  Craig L Slingluff; Gina R Petroni; Walter C Olson; Mark E Smolkin; Kimberly A Chianese-Bullock; Ileana S Mauldin; Kelly T Smith; Donna H Deacon; Nikole E Varhegyi; Sean B Donnelly; Caroline M Reed; Kristy Scott; Nadejda V Galeassi; William W Grosh
Journal:  Cancer Immunol Immunother       Date:  2015-11-18       Impact factor: 6.968

10.  Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses.

Authors:  Catherine Gérard; Nathalie Baudson; Thierry Ory; Jamila Louahed
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.